)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
BB Biotech
BB Biotech (BION) investor relations material
BB Biotech Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary23 Oct, 2026
Executive summary
Q3 NAV return was 5.6% in CHF and share-price return was 6.5%; 9M NAV return was 23.0%, below the NBI’s 31.8%.
Net profit was CHF 175.0 million in Q3 and CHF 604.8 million for 9M 2026.
~CHF 280 million of proceeds from two completed acquisitions was redeployed; 12 positions were added and eight exited, leaving 43 holdings.
Financial highlights
Q3 net profit was CHF 175.0 million versus CHF 447.6 million in Q3 2025; 9M net profit was CHF 604.8 million versus CHF 106.4 million.
9M operating income was CHF 637.3 million, including CHF 616.0 million in securities gains; profit before tax was CHF 604.9 million.
9M earnings per share were CHF 10.97 versus CHF 1.94 in 9M 2025; diluted EPS was also CHF 10.97.
NAV was CHF 3,259.5 million at September 30, up from CHF 2,778.8 million at December 31, 2025; NAV per share was CHF 59.10.
Outlook and guidance
Q4 milestones include empasiprubart, ORKA-001 and litifilimab data, plus US decisions on ivonescimab, BBP-418, povetacicept and anito-cel; FDA outcomes are not assured.
Since quarter-end, Vaxcyte reported positive pivotal Phase III results for its 31-valent pneumococcal vaccine candidate.
The annual dividend yield target is 3–5% from FY 2026, with the first payment expected in spring 2027; share buybacks complement the policy.
Valuation declines without deterioration in clinical prospects may present selective opportunities; portfolio exposure may increase as evidence and valuations warrant.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from BB Biotech
- Q3 saw a net loss but nine-month profit, high investment, and sector optimism amid volatility.BION
Q3 2024 - Q2 2026 NAV up 17.2% in CHF, net profit CHF 451mn, with new investments and M&A driving gains.BIONQ2 2026
- Share price outperformed, NAV discount narrowed, and portfolio diversification increased.BIONQ1 2026
- Net profit hit CHF 578 million, with strong returns, acquisitions, and a new buyback program.BIONQ4 2025
- Q3 2025 delivered 20% share price and 24% NAV growth, with robust profit and portfolio repositioning.BIONQ3 2025
- Q2 2025 saw strong USD returns, portfolio innovation wins, and a narrowed NAV discount despite FX drag.BIONQ2 2025
- Net profit rebounded to CHF 173 mn in H1 2024, driven by portfolio gains and clinical milestones.BIONQ2 2024
- Q1 2025 net loss of CHF 241 mn; NAV and share price down, portfolio refocused on larger firms.BIONQ1 2025
- Net profit recovery and strategic focus position BB Biotech for growth amid sector tailwinds.BIONQ4 2024
Next BB Biotech earnings date
Q4 202619 Feb, 2027
BB Biotech
Next BB Biotech earnings date
Q4 202619 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
BB Biotech AG is an investment company specializing in biotechnology. The company focuses on building a diversified portfolio of publicly listed biotech companies, primarily in the fields of drug development and medical research. BB Biotech's investments target companies involved in innovative treatments for diseases across therapeutic areas such as oncology, rare diseases, and infectious diseases. The company is headquartered in Schaffhausen, Switzerland, and its shares are listed on the SIX.